ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer

Qin Guo1,2,3, Tanja Grimmig4, Gabriel Gonzalez1,2, Anita Giobbie-Hurder5, Gretchen Berg1,2, Nolan Carr1, Brian J. Wilson3,10,11, Pallavi Banerjee1,3, Jie Ma3, Jason S. Gold6,7, Bisweswar Nandi6,7, Qin Huang8, Ana Maria Waaga-Gasser4, Christine G. Lian9, George F. Murphy9,10, Markus H. Frank3,10,11, Martin Gasser4,5, Natasha Y. Frank1,2,3,10,11.

1Department of Medicine, VA Boston Healthcare System, Boston, MA, USA
2Division of Genetics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
3Transplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
4Department of Surgery, University of Würzburg, Würzburg, Germany
5Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
6Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
7Department of Surgery, VA Boston Healthcare System, Boston, MA, USA
8Department of Pathology, VA Boston Healthcare System, Boston, MA, USA
9Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
10Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA
11Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA

¶Co-senior investigators

Running Title: ABCB5 controls tumor cell invasion

Correspondence should be addressed to: Natasha Y. Frank, VA Boston Healthcare System, 1400 VFW Parkway, Boston, MA, 02132, USA. Tel: +1 (617) 525-4451, Fax: +1 (617) 525-5333, E-mail: nyfrank@bwh.harvard.edu

Key words: colorectal cancer, metastasis, cancer stem cells, invasion, epithelial-mesenchymal transition (EMT)
ABSTRACT

ATP-binding cassette member B5 (ABCB5) mediates multidrug resistance (MDR) in diverse malignancies and confers clinically relevant 5-fluorouracil resistance to CD133-expressing cancer stem cells (CSCs) in human colorectal cancer (CRC). Because of its recently identified roles in normal stem cell maintenance, we hypothesized that ABCB5 might also serve MDR-independent functions in CRC. Here, in a prospective clinical study of 142 CRC patients, we found that ABCB5 mRNA transcripts previously reported not to be significantly expressed in healthy peripheral blood mononuclear cells are significantly enriched in patient peripheral blood specimens compared with non-CRC controls and correlate with CRC disease progression. In human-to-mouse CRC tumor xenotransplantation models that exhibited circulating tumor mRNA, we observed that cancer-specific ABCB5 knockdown significantly reduced detection of these transcripts, suggesting that the knockdown inhibited tumor invasiveness. Mechanistically, this effect was associated with inhibition of expression and downstream signaling of AXL receptor tyrosine kinase (AXL), a proinvasive molecule herein shown to be produced by ABCB5-positive CRC cells. Importantly, rescue of AXL expression in ABCB5-knockdown CRC tumor cells restored tumor-specific transcript detection in the peripheral blood of xenograft recipients, indicating that ABCB5 regulates CRC invasiveness, at least in part, by enhancing AXL signaling. Our results implicate ABCB5 as a critical determinant of CRC invasiveness and suggest that ABCB5 blockade might represent a strategy in CRC therapy, even independently of ABCB5’s function as an MDR mediator.
INTRODUCTION

Tumor development and progression have been associated, at the DNA level, with cumulative alterations in oncogenes, tumor suppressor genes, and repair/stability genes (1,2). At the cellular level, human cancers have been recognized to consist of phenotypically heterogeneous cell populations with variable ability for self-renewal and tumor propagation (3,4). This observation led to the development of the cancer stem cell (CSC) model of tumor initiation and growth (5), which has been broadly confirmed in multiple malignancies, including CRC (6-8). CSC have been shown to contribute to the failure of existing therapies to consistently eradicate malignant tumors through diverse molecular mechanisms (9), including epithelial-mesenchymal transition (EMT) (10) associated with the ability of human cancers to invade the vasculature and disseminate to novel anatomic locations leading to tumor progression and therapeutic resistance (11).

ABCB5 is a multidrug resistance (MDR) mediator expressed in diverse human malignancies (12), including CRC (13-15), where it is specifically overexpressed on therapy-resistant CD133(+) tumor subpopulations (16) previously found to represent CSC (6-8). ABCB5 confers CRC drug resistance to 5-fluorouracil (5-FU) (14,16). Whether ABCB5 might also serve a drug resistance-independent function in CRC, a possibility raised by recent studies in Abcb5 knockout (KO) mice that revealed key functions of this molecule in stem cell maintenance in non-malignant tissues (17), is currently unknown.

Colorectal cancer CSC can be identified by a number of molecular markers, including CD133 (6-8), ALDH1 (18), LGR5 (19) and LRIG1 (20). Several studies have shown that high expression of CSC markers in primary tumors could serve as a predictor of poor prognosis (reviewed in (21-23)) in CRC. In the current study, we hypothesized that drug transport-independent functions of ABCB5, first discovered in non-malignant tissue-specific stem cells (17), might also be relevant to malignant disease, in particular human CRC, where a requirement of ABCB5 for more efficient tumorigenic growth had previously been identified (16). Here, we first identified a potential role of ABCB5 in CRC invasiveness in human CRC patients, where ABCB5 mRNA levels detected in the peripheral blood markedly exceeded baseline threshold levels in healthy controls and served as an independent predictor of poor overall survival (OS).

In human-to-mouse CRC tumor xenotransplantation models that exhibited circulating tumor mRNA, we found that cancer-specific ABCB5 knockdown significantly reduced detectability of these transcripts, suggesting inhibition of tumor invasiveness through cancer-specific ABCB5 knockdown. Mechanistically, this effect was associated with inhibition of expression and downstream signaling of the receptor tyrosine kinase AXL, a pro-invasive molecule herein shown to be produced by ABCB5-positive CRC cells. Importantly, rescue of AXL expression in ABCB5 knockdown CRC tumor cells restored tumor-specific transcript detection in the peripheral blood of xenograft recipients indicating that ABCB5 regulates CRC invasiveness, at least in part, through enhancement of AXL signaling. Our results implicate ABCB5 as a novel determinant of CRC invasiveness and suggest that ABCB5 blockade might represent a novel strategy for CRC therapy, even in settings independent of its function as an MDR mediator.

RESULTS

Peripheral blood circulating ABCB5 mRNA levels are associated with poor overall survival (OS) in CRC. CSC have been associated with increased cancer virulence and deemed responsible for cancer metastatic progression and reduced patient survival (12,24). Based on our prior studies, which indicated that ABCB5 marks aggressive CSC in human CRC (16), we evaluated whether ABCB5 mRNA expression in peripheral blood specimens of patients with CRC correlates with poor prognosis. This study was conducted in a prospective cohort of 142 CRC patients undergoing treatment at the University of Würzburg Hospital, Germany (Supporting Table 1). Peripheral blood specimens obtained from
enrolled CRC patients prior to treatment initiation and from age-matched healthy controls were evaluated for ABCB5 mRNA expression. The analyses were performed using RNA isolated from all circulating cells collected by centrifugation. Since ABCB5 is expressed only at extremely low or undetectable levels in normal mononuclear blood cells (25,26), we posited that ABCB5 mRNA detectability in the peripheral blood of CTC patients might serve as an initial measure for assessment of tumor invasiveness in a clinical setting, as has been shown in other ABCB5-expressing cancers (26). In this study, we found significant enrichment of ABCB5 mRNA transcripts in CRC patients compared to healthy controls (P<0.0001, Fig. 1A). Moreover, peripheral blood ABCB5 mRNA levels were significantly associated with tumor location, UICC stage, N stage, and M stage (Supporting Table 2). Additionally, using the Kaplan -Meier method and the Cox model, we determined that peripheral blood ABCB5 mRNA levels served as an independent predictor of OS in CRC patients. ABCB5 expression values were hereby divided into 4 classes according to the quartiles of the distribution: from the 1st quartile (lowest expression levels) to the 4th quartile (highest expression levels). The distributions of OS were summarized using the Kaplan-Meier method with 95% confidence intervals (CI) estimated using the log (-log (endpoint)) methodology. The Kaplan-Meier curves and Cox model results revealed significant differences in OS for the different levels of ABCB5 expression, with the highest quartile of expression having the poorest OS. Median OS in the group with the highest ABCB5 expression was 26 months, compared to at least 76 months in the lower quartiles (Fig.1B, Table 1). The Cox model suggested two important predictors of OS in this cohort of patients: ABCB5 and UICC stage (Table 2). Compared to patients with the highest ABCB5 expression levels (4th quartile), patients in quartiles 1 and 2 with lower ABCB5 expression showed significant reductions of 87% and 75%, respectively, in the hazards of death (HR: 0.13, 95% CI: 0.05 to 0.35; HR: 0.25, 95% CI: 0.11 to 0.58). Additionally, patients with UICC stage 4 had significant increases in the hazard of death compared with UICC stage 1 (HR: 2.6, 95% CI: 1.02 to 6.6). These results suggested that ABCB5 might represent a novel predictor of poor OS in CRC patients and pointed to a potential functional role of ABCB5 in CRC invasiveness, providing a rationale for further dissection of ABCB5-dependent invasiveness in experimental model systems.

ABCB5 expression is enhanced in metastatic CRC cells. Based on our finding of enhanced ABCB5 mRNA expression in the peripheral blood of CRC patients as opposed to controls and the correlation of CRC ABCB5 expression with patient outcome, we hypothesized that human CRC cells with enhanced metastatic potential overexpressed ABCB5. We found that a cell line (SW620) derived from a metastatic lesion of a CRC patient expressed significantly higher levels of ABCB5 than one (SW480) derived from the primary tumor of the same patient (Fig. 2A, SW620 vs. SW480: 15.2 ± 2.3% vs.10.6 ± 1.9% cell positivity, P<0.05, mean ± SEM). This finding was experimentally recapitulated when examining in a CRC xenotransplantation model ABCB5 expression in COLO741 cells (a CRC cell line selected for its known metastatic potential) that had metastasized to the lung (COLO741MET) as opposed to COLO741 cells re-isolated from the primary tumor lesion (Fig. 2B, COLO741MET vs. COLO741: 27.0 ± 3.4% vs. 16.5 ± 3.3% cell positivity, P<0.01, mean ± SEM).

ABCB5 is required for tumor vascular invasion. Next, we utilized an established human-to-NSG mouse subcutaneous CRC tumor xenotransplantation model (6,7) to compare in vivo the vascular invasion potential of the COLO741MET vs. the COLO741 cell line (Fig. 3A). This was accomplished by measuring tumor-derived, human-specific mRNA transcripts, i.e. GAPDH, B2M, PPIA and MRPL19 (27), in murine peripheral blood samples harvested 8 weeks after primary tumor inoculation. We found that all four human CRC-derived mRNA transcripts were significantly enriched in the peripheral blood of mice injected with COLO741MET cells compared to mice injected with COLO741 cells (Fig. 3B). At this time point primary tumors in COLO741MET-injected mice had reached a mean volume of
605.4 ± 40.7 mm³ and in COLO741-injected mice of 250.2 ± 28.1 mm³ (n=8 mice/group, P<0.001, mean ± SEM). To test whether this enhanced vascular invasion was driven by ABCB5 overexpression, we performed shRNA-mediated ABCB5 knockdown (ABCB5 KD) in COLO741MET cells, which resulted in a >90% inhibition of ABCB5 mRNA expression and an approximately 50% reduction of ABCB5 protein expression due to relatively high ABCB5 protein stability in line with previous findings (28) (Fig. 3C, upper panels). While ABCB5 KD in human malignancies, including CRC, is known to inhibit primary tumor growth (16), and while in the current study primary tumors in COLO741MET ABCB5 KD injected mice were accordingly smaller than tumors injected with COLO741MET CONTROL cells (263.4 ± 47.5 vs. 662.8 ± 66.1 mm³, n=7 mice/group, P<0.001, mean ± SEM), there exists no known correlation between primary tumor size and the development of metastasis in experimental cancer xenotransplantation models or even in clinical findings in CRC patients (29,30). Thus, examination of tumor invasiveness at a specific time point was warranted. Compared to COLO741MET cells transfected with a control plasmid (COLO741MET CONTROL), mice xenografted with COLO741MET ABCB5 KD cells exhibited significantly reduced levels of human mRNA transcripts in their peripheral blood at 8 weeks after tumor inoculation (Fig. 3C, lower panels), indicating that the enhanced invasion potential of COLO741MET tumor cells is dependent on functional ABCB5.

To further investigate whether ABCB5-dependent metastatic propensity in vivo resulted from a role of the molecule in CRC invasiveness, we utilized an established in vitro trans-well assay to study the invasive capacity of WT vs. ABCB5 KD cell subsets and to examine the effect of monoclonal antibody (mAb)-mediated ABCB5 blockade on the invasiveness of CRC cells. First, consistent with our in vivo results, we found a significantly higher invasiveness of COLO741MET cells compared to COLO741 cells (invading cell numbers of COLO741MET vs. COLO741 cells: 139.3 ± 15.1 vs. 85.3 ± 11.1 cells, P<0.05, mean ± SEM) (Fig. 3D). This higher invasive capacity of COLO741MET cells was inhibited by shRNA-mediated ABCB5 knockdown, with a significant reduction of invading cell numbers in COLO741MET ABCB5 KD cultures compared to COLO741MET CONTROL cultures (COLO741MET ABCB5 KD vs. COLO741MET CONTROL: 59.3 ± 14.2 vs. 170.0 ± 36.6 cells, P<0.05, mean ± SEM) (Fig. 3D). A similar effect was observed in the setting of mAb-mediated ABCB5 blockade (17,25,31), which resulted in >90% inhibition of the invasiveness of COLO741MET cells and, similarly, in >90% inhibition of the invasiveness of additionally examined human SW620 cells derived from a metastatic lymph node of a CRC patient (ABCB5 mAb vs. isotype control treatment: 2.3 ± 0.6 vs. 160.7 ± 12.2 cells, P<0.001, mean ± SEM, COLO741MET; 7.3 ± 1.3 vs. 102.3 ± 27.2 cells, P<0.05, mean ± SEM, SW620) (Fig. 3D). Taken together, those findings revealed a novel role of ABCB5 in regulating CRC cell invasiveness in the specimens under study.

**ABCB5 promotes epithelial mesenchymal transition in CRC.** Epithelial mesenchymal transition (EMT) has been shown to play a critical role in enabling cancer tissue invasion through transitioning from a less aggressive, epithelial, to a more aggressive, mesenchymal, phenotype (10). Based on our results that ABCB5 is required for CRC cell invasion and hematological spread, we hypothesized that ABCB5 expression is associated with EMT and might regulate the mesenchymal cellular phenotype in CRC. First, we found that morphologically, in contrast to in vivo-unpassaged, parental COLO741 cells that exhibited flattened and polygonal shapes consistent with epithelial cell characteristics (Fig.4A), COLO741MET cells with higher ABCB5 expression (as shown in Fig. 2B) appeared smaller, spindle-shaped and significantly more elongated (P<0.01) with tapering cytoplasmic poles consistent with a mesenchymal phenotype (Fig. 4A). In line with an EMT phenotype, COLO741MET cells expressed lower mRNA levels of the epithelial marker E-cadherin (CDH1) and higher mRNA levels of the mesenchymal markers N-cadherin (CDH2) and Vimentin (VIM) compared to parental COLO741 cells (Fig. 4A). Western Blot
analyses also revealed high protein levels for CDH2 and VIM in COLO741MET vs. COLO741 cells (Fig. 4A), whereas CDH1 protein was undetectable by Western Blot in either cell line. Similarly, patient metastatic lymph node-derived SW620 cells also expressed higher levels of VIM and lower levels of CDH1 compared to their SW480 counterparts derived from the primary colonic adenocarcinoma of the same patient at both mRNA and protein levels (Fig. 4A). In both SW480 and SW620 cell lines, CDH2 was not detectable at the mRNA or the protein levels (Fig. 4A).

Next, we examined whether ABCB5 is required for the maintenance of the mesenchymal phenotype in CRC cells using either mAb- or shRNA-mediated ABCB5 blockade. ABCB5 inhibition in COLO741 cells through either mAb treatment or ABCB5 KD resulted in attenuated expression of CDH2 and VIM and enhanced expression of CDH1 at the mRNA level and in attenuated CDH2 and VIM expression at the protein level, while CDH1 was not detectable at the protein level in either ABCB5 blockade or control cultures (Fig. 4B). Similar reciprocal changes in epithelial and mesenchymal marker expression were observed as a result of mAb-based ABCB5 blockade in the metastatic cell line SW620, which also exhibited enhanced CDH1 and reduced VIM mRNA and protein expression in ABCB5 mAb-compared to isotype control-treated cultures (Fig. 4B). These results revealed a novel functional role of ABCB5 in the maintenance of a mesenchymal phenotype in human CRC cells and provided proof-of-principle that this phenotype can be targeted through ABCB5 mAb blockade in a translationally relevant manner.

**ABCB5 promotes tumor invasion through regulation of AXL.** Recent studies have shown that the receptor tyrosine kinase AXL, which correlates with adverse CRC prognosis (32), is responsible for EMT induction in other malignancies (33,34). We found that AXL mRNA expression was diminished in COLO741 ABCB5 KD CRC cell cultures by >90% and that AXL protein expression was reduced in these cells by >50% compared to control-transfected cells (Fig. 5A). Furthermore, mAb-mediated ABCB5 blockade consistently inhibited expression of AXL in all of four CRC cell lines examined (COLO741, SW620, HT29 and HCT116, with ABCB5(+) tumor cell frequencies ranging from 9% to 27%), as determined by Western Blot analysis (Fig. 5A), and also inhibited, to a lesser degree, its downstream target phospho-AKT. The functional relationship between ABCB5 and AXL was supported by significantly upregulated AXL expression at both mRNA and protein levels in untreated ABCB5(+) cells sorted from all four cell lines by flow cytometry (Fig. 5B). Moreover, AXL expression (as determined at both mRNA and protein levels) and downstream signaling (p-AKT/AKT ratios) were enhanced in metastasis-derived COLO741MET- vs. parental COLO741 cells (Fig. 5C). To investigate whether ABCB5-driven CRC invasiveness is mediated by AXL in vivo, we examined whether AXL over-expression in COLO741-ABCB5 KD cells could restore hematological cancer dissemination in an established human-to-NSG mouse subcutaneous tumor xenotransplantation model (6,7), in which mice were grafted with either COLO741 ABCB5 KD cells or their respective controls, or COLO741 ABCB5 KD cells transfected with AXL or their respective controls. Murine recipient peripheral blood samples were collected 16 weeks after tumor inoculation and examined for expression of human-specific GAPDH, B2M, PPIA and MRPL19 mRNA transcripts (27). We found that human cancer-derived mRNA transcript levels were significantly reduced in peripheral blood samples of NSG mice transplanted with COLO741 ABCB5 KD cells compared to controls (Fig. 5D). Moreover, exogenous restoration of AXL expression in ABCB5 KD cells (Fig. 5E, left and center panels) significantly reversed this effect (Fig. 5E, right panel). Taken together, these results indicated that ABCB5-driven hematological CRC dissemination is mediated, at least in part, through regulation of AXL.

**ABCB5-mediated EMT induction is dependent on an IL-8/AXL signaling cascade.** Previous studies revealed a critical role of IL-8 in the induction of CRC EMT (35,36). Based on our discovery of a novel functional relationship between ABCB5 and AXL, and on the
established molecular role of ABCB5 in IL-8 production (13), we hypothesized that ABCB5 might also employ the IL-8 pathway to sustain AXL-mediated EMT in CRC. To test this hypothesis, we first examined the effect of ABCB5 blockade on IL-8 production by CRC cells. We found that ABCB5 mAb treatment resulted in a significant reduction of IL-8 production in all four CRC cell lines examined (Fig. 6A, left panel). A similar effect was observed in the setting of shRNA-mediated ABCB5 KD, tested in an exemplary manner in COLO741 cells (Fig. 6A, right panel). Additionally, exogenous administration of recombinant IL-8 reversed ABCB5 mAb-induced inhibition of AXL expression in HCT116, HT29, SW620 and COLO741 CRC cell cultures (Fig. 6B) as evidenced by quantitative ImageJ-based densitometry analyses of the Western blot data, which revealed significant IL-8-induced augmentation of AXL levels compared to the impaired levels (63% ± 6% inhibited, P<0.01, mean ± SEM) observed in ABCB5-blocked cultures, by 40% ± 18%, P<0.05, mean ± SEM, at 1 ng/ml IL-8 concentrations, indicating that ABCB5 control of AXL expression is mediated, at least in part, via IL-8. Moreover, exogenous administration of recombinant IL-8 was also associated with restoration of mesenchymal marker expression (CDH2 and VIM in COLO741 cells and VIM in SW620 cells, Fig. 6C), and inhibition of epithelial marker expression (CDH1) in SW620 cells (Fig. 6C). Specifically, quantitative ImageJ-based densitometry analyses of the Western blot data showed significant IL-8-induced dose-dependent increase in CDH2 and VIM (up to 68% and 90% respectively, at 1 ng/ml IL-8 concentration, P<0.05), compared to the impaired levels of CDH2 (77% inhibited) and VIM (85% inhibited) observed in ABCB5-blocked COLO741 cultures (Fig. 6C, left panel). Similar results were observed in SW620 cultures, where quantitative Western blot analyses showed significant IL-8-induced dose-dependent increase in VIM (up to 30% at 1 ng/ml IL-8 concentration, P<0.05) compared to the impaired levels of VIM (62% inhibited) observed in ABCB5-blocked cultures (Fig. 6C, right panel). In addition, SW620 cultures exhibited IL-8-induced dose-dependent attenuation of epithelial marker CDH1 expression (75% inhibited) at 1 ng/ml IL-8 concentration, P<0.05, compared to the 35% augmentation of CDH1 observed in the setting of ABCB5 blockade (Fig. 6C, right panel). These results indicate that ABCB5 control of EMT marker expression is also mediated, at least in part, via IL-8.

**DISCUSSION**

Previously, ABCB5 has been shown to represent a clinically relevant MDR mechanism, based on drug efflux function, in diverse human malignancies (13,16,37-39), which can be therapeutically targeted in CSC subpopulations through mAb-mediated functional blockade that inhibits ABCB5-mediated drug efflux, or through therapeutic ablation of ABCB5-expressing, drug-effluxing CSCs via antibody dependent cell-mediated cytotoxicity (ADCC) (31,37). In contrast, drug efflux-independent functions of ABCB5 in CSC and normal tissue-specific stem cells are only beginning to be elucidated: For example, ABCB5 has been shown to control a pro-inflammatory cytokine signaling axis involving IL-8 production and IL-8-dependent CSC maintenance in human melanoma (13) and to exert anti-apoptotic functions in normal tissue-specific stem cells through p53 stabilization and regulation of BCL-2/BCL-X expression (17).

In CRC, ABCB5 has been shown to confer therapeutic resistance to 5-fluorouracil (5-FU) (14,16) and ABCB5-mediated chemoresistance has been found to be positively regulated by c-MYC (14), whereas microRNA-522 (miR-522) could reverse ABCB5-mediated drug resistance as a negative regulator of ABCB5 expression (15). However, drug resistance-independent functions of ABCB5 in CRC have not been reported prior to our current study.

Here, using gene knockdown- and mAb-based ABCB5 inhibition strategies in vitro or ABCB5 blockade in tumor xenotransplantation models in vivo, we demonstrate for the first time that ABCB5 controls CRC cell invasiveness, unrelated to its previously established function as a drug resistance mechanism.
Mechanistically, we show that this novel function involves, at least in part, ABCB5-mediated control of IL-8 production paralleling findings previously established in melanoma (13) and, additionally, a downstream pathway of IL-8-dependent induction of AXL, a receptor tyrosine kinase with known roles in CRC invasiveness (32). Consistent with these results, we provide initial evidence for a role of ABCB5 in the EMT phenotype of colorectal cancer cells, which has also been previously linked to tumor invasiveness, including in CRC (40). Thus, our study implicates ABCB5 as a novel link between drug resistance, EMT and tumor invasiveness in CRC, with potentially important implications for CRC therapy and prognosis. For example, the ABCB5-regulated downstream molecules IL-8 and AXL confer tumor resistance to EGFR-targeted therapies (41-43), which are widely used for the treatment of advanced CRC (44-46). Further exploration of ABCB5 as a potential novel target to sensitize EGFR-resistant CRC tumors to therapy might therefore be warranted. With regard to the potential relevance of our findings to clinical CRC progression and prognosis, we found in an initial clinical study a specific association between increased circulating ABCB5 mRNA levels and poor OS in CRC patients. This result parallels previous findings in clinical melanoma, where circulating ABCB5 mRNA levels had significant prognostic value in inferring disease recurrence (26). Importantly, circulating ABCB5 mRNA is not expressed at significant levels in the peripheral blood of healthy humans (25) and, when detectable at significant levels in cancer patients, has been shown to arise from disseminated tumor cells (26,47-49), suggesting that circulating ABCB5 mRNA detected in CRC patients in the current study similarly arose from tumor cell bloodstream invasion. Our findings in human-to-mouse CRC xenotransplantation models clearly support this notion, by documenting the functional role of ABCB5 in human CRC tumor cell blood stream invasion. While we cannot rule out entirely that differences in primary tumor lesions may have influenced metastatic behavior in our experiments, such correlations between primary tumor size and the development of metastasis have not previously been observed in experimental cancer xenotransplantation models (30). Our results provide a rationale for future studies aimed at correlating circulating ABCB5 mRNA levels with the prognostic value of ABCB5(+) CTC numbers in CRC patients.

In summary, our finding that ABCB5 promotes tumor cell invasion in CRC suggests that novel ABCB5-targeted strategies in this malignancy might have the potential to disrupt two distinct but apparently related features of tumor aggressiveness, i.e., as previously shown, drug resistance (28), and, based on current results, invasive tumor progression.

**EXPERIMENTAL PROCEDURES**

**Patients.** This study prospectively enrolled patients undergoing treatment for CRC at the University Hospital of Würzburg from 01/2003 to 12/2008. Of 670 patients enrolled, 142 were included in this study based on the availability of histologically confirmed primary tumors or metastases and of pre-treatment-obtained peripheral blood samples. Patient characteristics are summarized in Supplemental Table1. All patients were followed-up regularly at 3- to 6-month intervals in accordance with the guidelines for the German Tumor Centers (completeness index of 0.96 (50)). Median follow-up in the data set for the CRC patients was 69 months (95% CI: 62 to 73 months), which is based on a Kaplan-Meier estimate with an inverted censor. UICC stage I and stage II patients underwent surgical resection without adjuvant chemotherapy. Stage III colon cancer patients were treated with adjuvant chemotherapy (FOLFOX-4 or FOLOFOX-6 regimens) after surgical resection. Stage III rectal cancer patients were treated with neoadjuvant chemoradiation (2 cycles of 5 FU +/- Oxaliplatin and cumulative 54 Gy of Radiation prior to surgery followed by an additional 4 cycles of chemotherapy (FOLFOX-4 or FOLFOX-6 regimens) after the surgery. Stage IV patients were treated with several regimens (mostly FOLFOX or FOLFIRI +/- Bevacizumab or Cetuximab) with neoadjuvant or palliative intention to treat. The study was approved by the University Hospital of Würzburg Ethics Committee and it abides by the Declaration of Helsinki principles. All patients
enrolled in the study signed the informed consent.

**Quantitative RT-PCR analyses.** Peripheral blood (7.5 ml collected in EDTA-containing vacutainers) was obtained from each patient before treatment initiation. After density centrifugation through Ficoll-Paque (Pharmacia, Freiburg, Germany; 30 min, 400 x g), peripheral mononuclear blood cells were harvested and washed twice in phosphate-buffered saline (PBS). Cell pellets were snap-frozen in liquid nitrogen and stored at -80°C until further use. mRNA was extracted from 1x10⁶ cells using Trizol reagent (Invitrogen, Darmstadt, Germany) according to the manufacturer’s recommendations. cDNA synthesis was carried out using the iScript cDNA Synthesis Kit (Promega, Mannheim, Germany). The following primers were used: ABCB5 sense: 5’-CACAAAAGGCCATTCAGGCT-3’, ABCB5 antisense 5’-GCTGAGGAATCCACCCAATCT-3’, β-actin sense: 5’-CCTGGCAACCACGACAAT-3’ and β-actin antisense: 5’-GCCGATCCACACGGAGTACT-3’. All PCR reactions were carried out with a DNA Engine Opticon 2 System (MJ Research, Biozym). Gene expression levels were normalized to β-actin and shown as ΔCt calculated as Ct for gene of interest minus Ct for β-actin.

For quantitative RT-PCR analyses of cultured CRC cells, total RNA was isolated using an RNeasy plus kit (Qiagen) as previously described (51). cDNA was synthesized from 1 µg of total RNA using the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Invitrogen) according to the manufacturer’s protocol. Quantitative RT-PCR was performed using the TaqMan® Gene Expression Master Mix (AB Applied Biosystems) with primers and TaqMan probes listed as follows: CDH1 (Hs01013953), CDH2 (Hs00983061), VIM (Hs00958112), GAPDH (Hs99999905), B2M (Hs00187842), PPIA (Hs99999904), MRPL19 (Hs00608519) and ACTB (4352341E). All PCR reactions were carried out with a GeneAmp 7000 Sequence Detection System (Applied Biosystems) and assessed as described previously (52).

**Cell Culture.** The authenticated human CRC cell lines HCT116, HT29 and SW620 were obtained from American Type Culture Collection. The authenticated human CRC cell line COLO741 was purchased from Sigma-Aldrich. Cells were cultured in RPMI 1640 medium (Lonza Bio-Whittaker) supplemented with 10% (v/v) FBS (Invitrogen Gibco) and 1% (v/v) penicillin/streptomycin (Lonza Bio-Whittaker).

**Generation of Stable Knockdown and Overexpressing Colorectal Cancer Cell lines.** Generation of stable COLO741 ABCB5 knockdown (KD) or control cell lines was accomplished by retroviral infection followed by puromycin selection (1 µg/mL). Briefly, using FuGENE HD Transfection Reagent, 293T cells were co-transfected with a retroviral vector pSMP expressing a shRNA of interest, a plasmid pCMV-Gag-Pol expressing the retroviral structure proteins and a plasmid mediating viral entry. Retroviral stocks were collected as culture supernatants 48 hours post-transfection and used for infection of COLO741 cells. The ABCB5 shRNA target sequence 5’-CCTCGAAGAAAGCACAGATTA-3’ was chosen among other targets tested based on the highest ABCB5 knockdown efficiency. The ABCB5 mRNA knockdown efficiency was confirmed by TaqMan® Gene Expression Assays (Life Technology, Hs00698751_m1) using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal control (Life Technology, Hs99999905_m1). Reduction of ABCB5 protein expression in ABCB5 KD cell lines was confirmed by flow cytometry. Stable COLO741 ABCB5 KD AXL-overexpressing and COLO741 ABCB5 KD-control cell lines were generated by transfection of plasmids, pCMV-AXL and pCMV-entry (Origene), using FuGENE HD Transfection Reagent. Stably transfected cell clones were selected using Geneticin (1 mg/mL). AXL overexpression was confirmed at the mRNA level by qPCR using TaqMan® Gene Expression Assays (Life Technology, Hs01064445_m1), using GAPDH as internal control (Life Technology, Hs99999905_m1). AXL protein expression was examined by
Western blot analyses using goat anti-AXL polyclonal Ab.

**Generation of a metastatic CRC Cell Pool COLO741MET.** COLO741 cells were xenografted subcutaneously into the right flanks of recipient NSG mice (1 × 10^6 per inoculum). At 8 weeks after tumor cell inoculation, mice were euthanized, and lung metastases were isolated under a dissecting microscope. The tissues were minced and digested in PBS containing 5 mg/ml collagenase IV (Worthington-Biochem), 1 mM CaCl_2, 1% (v/v) penicillin/streptomycin (Lonza Bio-Whittaker) and 1% (v/v) antibiotic-antimycotic (Invitrogen Gibco) at 37°C for 1 hour with constant shaking at 250 rpm. Cells were filtered through a 40-µm cell strainer (BD Falcon), pelleted, washed twice with PBS and transferred to 25 cm² culture flasks. Dissociated cell cultures were incubated at 37°C with 5% CO_2 in RPMI 1640 medium (Lonza Bio-Whittaker) supplemented with 10% (v/v) FBS (Invitrogen Gibco) and 1% (v/v) penicillin/streptomycin (Lonza Bio-Whittaker). The cells were passed every 2-3 days and subjected to controlled trypsinizations to remove any contaminating fibroblasts.

**Antibodies.** The following primary antibodies were used in flow cytometry experiments: mouse monoclonal anti-ABCB5 antibody (clone 3C2-1D12) (17,25,31,37,51,53) and anti-AXL polyclonal goat antibody (R&D systems). MOPC-31C mouse isotype (BD Pharmingen) and polyclonal goat IgG (R&D systems) were used as primary control antibodies. The secondary antibodies were rat anti-mouse IgG1-APC antibody (BD Pharmingen) and donkey anti-goat IgG-PE (R&D systems). For the Western blots, the following antibodies were purchased from R&D Systems: human AXL polyclonal goat antibody, goat anti-rabbit IgG-HRP affinity-purified polyclonal antibody, goat anti-mouse IgG-HRP affinity-purified polyclonal antibody, and rabbit anti-goat IgG-HRP affinity-purified polyclonal antibody. In addition, the following antibodies were purchased from Cell Signalling Technology: β-Actin (D6A8) rabbit monoclonal antibody, E-Cadherin (24E10) rabbit monoclonal antibody, Vimentin (D21H3) rabbit monoclonal antibody, and N-Cadherin (D4R1H) rabbit monoclonal antibody. The following antibodies were used for functional ABCB5 inhibition studies: mouse monoclonal anti-ABCB5 antibody (clone 3C2-1D12) (25) and isotype control mAb (clone MOPC31C, Sigma, St Louis, MO).

**Transwell in vitro invasion assays.** The effect of ABCB5 on cell invasion was determined using BioCoat™ Matrigel® invasion chambers (Coming, Corning, NY) according to the manufacturer’s instructions. Briefly, cells were seeded on the Matrigel-coated upper inserts in serum-free RPMI 1640 medium at a density of 5×10^4 cells per well for the COLO741, COLO741MET, COLO741MET CONTROL and COLO741MET ABCB5 KD lines and of 2×10^5 cells per well for the SW620 line. The bottom wells were filled with 10% fetal bovine serum (FBS)-containing medium. For mAb-mediated ABCB5 blockade, isotype control mAb or anti-ABCB5 mAb was added fresh daily to both the upper and lower chambers at the concentration of 50 µg/ml. All studies were conducted in triplicates. After 24 or 48 hours of incubation, the inserts were removed and cells invading the lower chamber were stained with the Diff-Quik™ kit (Andwin Scientific, North Carolina, IL). The cells were photographed at a 10x magnification under a Nikon Eclipse TI microscope and counted in four randomly selected microscopic fields per well.

**In vivo cell invasion assays.** For in vivo cellular invasion analyses, we utilized a human-to-mouse xenotransplantation model as described previously (48). COLO741 and COLO741MET, as well as COLO741MET CONTROL and COLO741MET ABCB5 KD cells, were xenografted subcutaneously into the right flanks of recipient NSG mice (1 × 10^6 per inoculum, n=8 mice per group). At 8 weeks post transplantation, mice were euthanized and blood specimens were collected by cardiac puncture (48). Erythrocytes were lysed using the modified hypotonic shock method described previously (54). Briefly, 8.2 ml of ice-cold distilled water was added to 800 µl of the murine blood at 4°C. The tubes were lightly agitated for 15 s, then 1 ml of ice-cold 10×PBS was added to restore the isotonicity of the blood sample. After that, cell
suspensions were centrifuged at 250 × g for 5 min at 4 °C to pellet the cells. The cell pellets were washed twice with ice-cold 1×PBS, re-suspended in 1×RLT-plus buffer (Qiagen) containing 1% (v/v) β-mercaptoethanol and stored at -80°C for further analysis.

Flow Cytometry. Cells were harvested using Versene (Invitrogen), passed through a 40-µm nylon mesh to exclude aggregates and examined using trypan blue for cell viability, as described previously (52). Analysis of ABCB5 and AXL expression was done by single color flow cytometry as described previously (52).

Western Blots. Protein lysates from cultured cells were prepared using 10xCell Lysis Buffer (Cell Signaling) supplemented with 1x complete protease inhibitor cocktail (Roche). For tumor tissues, total protein was purified using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Immunoblotting was performed as described previously (51). Semi-quantitative analysis of western blots was performed using LI-COR software Image Studio Lite (LI-COR, http://www.licor.com/bio/products/software/).

IL-8 ELISA and IL-8 rescue assays. Supernatants from CRC cell cultures treated with either isotype control or anti-ABCB5 mAb were collected, centrifuged to remove particulates, aliquoted and stored at -80°C before analysis. IL-8 concentration was measured using the Human CXCL8/IL8 Quantikine ELISA Kit (R&D Systems) according to the manufacturer’s instructions. For IL-8 rescue experiments, CRC cells were cultured in the presence of either vehicle control or recombinant IL-8 (R&D Systems) at the indicated concentrations for 72 hours.

Animals. Immunodeficient male and female NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>/SzJ (NSG) mice were purchased from Jackson Laboratory. All animals were maintained in accordance with the Institutional Guidelines of the VA Boston Healthcare System, Harvard Medical School.

Statistical Methods. For the clinical study, ABCB5 expression was summarized according to patient demographic or disease characteristics using the Wilcoxon rank-sum test (two categories) or the Kruskal-Wallis test (3 or more categories). ABCB5 mRNA expression levels were divided into 4 classes according to the quartiles of the distribution of expression values. The distributions of overall survival (OS) were summarized using the method of Kaplan-Meier with 95% confidence intervals (CI) estimated using log (-log (endpoint)) methodology. Cox proportional hazards regression models were fit to each of the time-to-event outcomes. ABCB5 expression (quartiles) was included as an independent variable in all Cox models related to that biomarker. Additional candidate independent predictors were patient gender, tumor location, tumor grade (grade 1, 2 vs. 3), UICC stage, T stage, N stage, and M stage, and patient age divided at the median (66 years). Standard model-building techniques were used. Predictors were considered statistically significant and included in the final model if the Wald chi-squared P value was < 0.05 or if the model fit was significantly improved by including a predictor with a P value between 0.05-0.065 based on a log-likelihood test. Spearman correlation coefficients were used to describe the relationships between expression levels of the four biomarkers. Comparisons of ABCB5 expression between patients with CRC and controls were based on Wilcoxon rank-sum tests. The OS, determined as time in months from treatment initiation to death from any cause was chosen as the endpoint definition. In other, non-clinical experimental studies, statistical differences between expression levels of markers or between surviving cell fractions were determined by using paired or unpaired t-tests where appropriate, with 2-sided P values of P < 0.05 considered significant.

ONLINE SUPPLEMENTAL MATERIAL. Supplemental Tables 1&2 are included.
ACKNOWLEDGMENTS: This work was supported by VA BLR&D 1I01BX000516 and VA RR&D 1I01RX000989 Merit Review Awards, and DOD translational team science award to N.Y.F., and NIH/National Cancer Institute grants R01CA113796, R01CA158467 and R01CA138231 to M.H.F.

CONFLICT OF INTEREST STATEMENT: N.Y.F. and M.H.F. are co-inventors of the ABCB5-related US patent 7,928,202 (Targeting ABCB5 for cancer therapy) assigned to Brigham and Women’s Hospital, Boston, Massachusetts, and licensed to Ticeba GmbH (Heidelberg, Germany) and Rheacell GmbH & Co. KG (Heidelberg, Germany). M.H.F. serves as a scientific advisor to Ticeba GmbH and Rheacell GmbH & Co. KG.

AUTHOR CONTRIBUTIONS: Q.G., M.H.F., M.G. and N.Y.F. designed the study, Q.G., T.G., G.B., B.J.W., G.G., P.B., N.C., J.M. and N.Y.F. performed the experiments, Q.G., T.G., A.G-H., M.H.F., C.G.L, G.F.M., M.G., and N.Y.F. analyzed the results, J.S.G, B.N., Q.H., A.M.W. and M.G. provided clinical specimens, A.G-H. performed the statistical analyses, Q.G, T.G, M.H.F., M.G., and N.Y.F. wrote the manuscript.

REFERENCES

1. Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M. R. (2004) A census of human cancer genes. Nat Rev Cancer 4, 177-183
2. Vogelstein, B., and Kinzler, K. W. (2004) Cancer genes and the pathways they control. Nat Med 10, 789-799
3. Bruce, W. R., and Van Der Gaag, H. (1963) A Quantitative Assay For The Number Of Murine Lymphoma Cells Capable Of Proliferation In Vivo. Nature 199, 79-80
4. Fidler, I. J., and Hart, I. R. (1982) Biological diversity in metastatic neoplasms: origins and implications. Science 217, 998-1003
5. Reya, T., Morrison, S. J., Clarke, M. F., and Weissman, I. L. (2001) Stem cells, cancer, and cancer stem cells. Nature 414, 105-111
6. Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., and De Maria, R. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115
7. O'Brien, C. A., Pollett, A., Gallinger, S., and Dick, J. E. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110
8. Zhu, L., Gibson, P., Curle, D. S., Tong, Y., Richardson, R. J., Bayazitov, I. T., Poppleton, H., Zakharenko, S., Ellison, D. W., and Gilbertson, R. J. (2009) Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457, 603-607
9. Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284
10. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., Campbell, L. L., Polyak, K., Brisken, C., Yang, J., and Weinberg, R. A. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715
11. Thiery, J. P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454
12. Frank, N. Y., Schatton, T., and Frank, M. H. (2010) The therapeutic promise of the cancer stem cell concept. J Clin Invest 120, 41-50
13. Wilson, B. J., Saab, K. R., Ma, J., Schatton, T., Putz, P., Zhan, Q., Murphy, G. F., Gasser, M., Waaga-Gasser, A. M., Frank, N. Y., and Frank, M. H. (2014) ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res 74, 4196-4207
14. Kugimiya, N., Nishimoto, A., Hosoyama, T., Ueno, K., Enoki, T., Li, T. S., and Hamano, K. (2015) The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells. *J Cell Mol Med*

15. Yang, G., Jiang, O., Ling, D., Jiang, X., Yuan, P., Zeng, G., Zhu, J., Tian, J., Weng, Y., and Wu, D. (2015) MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5. *Mol Med Rep* **12**, 3930-3936

16. Wilson, B. J., Schatton, T., Zhan, Q., Gasser, M., Ma, J., Saab, K. R., Schanche, R., Waaga-Gasser, A. M., Gold, J. S., Huang, Q., Murphy, G. F., Frank, M. H., and Frank, N. Y. (2011) ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. *Cancer Res* **71**, 5307-5316

17. Ksander, B. R., Kolovou, P. E., Wilson, B. J., Saab, K. R., Guo, Q., Ma, J., McGuire, S. P., Gregory, M. S., Vincent, W. J., Perez, V. L., Cruz-Guilloty, F., Kao, W. W., Call, M. K., Tucker, B. A., Zhan, Q., Murphy, G. F., Lathrop, K. L., Alt, C., Mortensen, L. J., Lin, C. P., Zieske, J. D., Frank, M. H., and Frank, N. Y. (2014) ABCB5 is a limbal stem cell gene required for corneal development and repair. *Nature* **511**, 353-357

18. Huang, E. H., Hynes, M. J., Zhang, T., Gisteller, C., Dontu, G., Appelman, H., Fields, J. Z., Wicha, M. S., and Boman, B. M. (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res* **69**, 3382-3389

19. Kemper, K., Prasetyanti, P. R., De Lau, W., Rodermond, H., Clevers, H., and Medema, J. P. (2012) Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. *Stem Cells* **30**, 2378-2386

20. Powell, A. E., Wang, Y., Li, Y., Poulin, E. J., Means, A. L., Washington, M. K., Higginbotham, J. N., Juchheim, A., Prasad, N., Levy, S. E., Guo, Y., Shyr, Y., Aronow, B. J., Haigis, K. M., Franklin, J. L., and Coffey, R. J. (2012) The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. *Cell* **149**, 146-158

21. Chen, J., Xia, Q., Jiang, B., Chang, W., Yuan, W., Ma, Z., Liu, Z., and Shu, X. (2015) Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. *PLoS One* **10**, e0145164

22. Chen, Q., Zhang, X., Li, W. M., Ji, Y. Q., Cao, H. Z., and Zheng, P. (2014) Prognostic value of LGR5 in colorectal cancer: a meta-analysis. *PLoS One* **9**, e107013

23. Chen, S., Song, X., Chen, Z., Li, X., Li, M., Liu, H., and Li, J. (2013) CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. *PLoS One* **8**, e56380

24. Visvader, J. E., and Lindeman, G. J. (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* **8**, 755-768

25. Frank, N. Y., Pende, S. S., Lapchak, P. H., Margaryan, A., Shlain, D., Doeing, C., Sayegh, M. H., and Frank, M. H. (2003) Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. *J Biol Chem* **278**, 47156-47165

26. Reid, A. L., Millward, M., Pearce, R., Lee, M., Frank, M. H., Ireland, A., Monshizadeh, L., Rai, T., Heenan, P., Medic, S., Kumarasinghe, P., and Ziman, M. (2013) Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. *Br J Dermatol* **168**, 85-92

27. Kheirelseid, E. A., Chang, K. H., Newell, J., Kerin, M. J., and Miller, N. (2010) Identification of endogenous control genes for normalisation of real-time quantitative PCR data in colorectal cancer. *BMC Mol Biol* **11**, 12

28. Wilson, B. J., Schatton, T., Frank, M. H., and Frank, N. Y. (2011) Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. *Current colorectal cancer reports* **7**, 128-135

29. Wolmark, N., Cruz, I., Redmond, C. K., Fisher, B., and Fisher, E. R. (1983) Tumor size and regional lymph node metastasis in colorectal cancer. A preliminary analysis from the NSABP clinical trials. *Cancer* **51**, 1315-1322
30. Quintana, E., Piskounova, E., Shackleton, M., Weinberg, D., Eskieocak, U., Fullen, D. R., Johnson, T. M., and Morrison, S. J. (2012) Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. *Sci Transl Med* **4**, 159ra149

31. Frank, N. Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A. M., Gasser, M., Sayegh, M. H., Sadec, W., and Frank, M. H. (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. *Cancer Res* **65**, 4320-4333

32. Dunne, P. D., McArt, D. G., Blayney, J. K., Kalimutho, M., Greer, S., Wang, T., Srivastava, S., Ong, C. W., Arthur, K., Loughrey, M., Redmond, K., Longley, D. B., Salto-Tellez, M., Johnston, P. G., and Van Schaeybroeck, S. (2014) AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. *Clin Cancer Res* **20**, 164-175

33. Gjerdrum, C., Tiron, C., Hoiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T., Micklem, D. R., Akslen, L. A., Glackin, C., and Lorens, J. B. (2010) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. *Proc Natl Acad Sci U S A* **107**, 1124-1129

34. Asiedu, M. K., Beauchamp-Perez, F. D., Ingle, J. N., Behrens, M. D., Radisky, D. C., and Knutson, K. L. (2014) AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. *Oncogene* **33**, 1316-1324

35. Fernando, R. I., Castillo, M. D., Litzinger, M., Hamilton, D. H., and Palena, C. (2011) IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. *Cancer Res* **71**, 5296-5306

36. Huang, W. L., Yang, M. H., Tsai, M. L., Lan, H. Y., Su, S. H., Chang, S. C., Teng, H. W., Yang, S. H., Lan, Y. T., Chiou, S. H., and Wang, H. W. (2011) SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. *Gastroenterology* **141**, 279-291, 291 e271-275

37. Schatton, T., Murphy, G. F., Frank, N. Y., Yamaura, K., Waaga-Gasser, A. M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L. M., Weishaupt, C., Fuhlbrigge, R. C., Kupper, T. S., Sayegh, M. H., and Frank, M. H. (2008) Identification of cells initiating human melanomas. *Nature* **451**, 345-349

38. Cheung, S. T., Cheung, P. F., Cheng, C. K., Wong, N. C., and Fan, S. T. (2011) Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. *Gastroenterology* **140**, 344-355

39. Chartrain, M., Riond, J., Punnett, A., Vandenbergh, I., Gomes, B., Lamant, L., Meyer, N., Gairin, J. E., Guilbaud, N., and Annereau, J. P. (2012) Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. *PLoS One* **7**, e36762

40. Bates, R. C., DeLeo, M. J., 3rd, and Mercurio, A. M. (2004) The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. *Exp Cell Res* **299**, 315-324

41. Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., Choi, Y. J., Choi, C. M., Kim, S. W., Jang, S. J., Park, Y. S., Kim, W. S., Lee, D. H., Lee, J. S., Miller, V. A., Arcila, M., Ladanyi, M., Moonsamy, P., Sawyers, C., Boggon, T. J., Ma, P. C., Costa, C., Taron, M., Rosell, R., Halmos, B., and Bivona, T. G. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. *Nat Genet* **44**, 852-860

42. Meyer, A. S., Miller, M. A., Gertler, F. B., and Lauffenburger, D. A. (2013) The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. *Sci Signal* **6**, ra66

43. Liu, Y. N., Chang, T. H., Tsai, M. F., Wu, S. G., Tsai, T. H., Chen, H. Y., Yu, S. L., Yang, J. C., and Shih, J. Y. (2015) IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. *Oncotarget* **6**, 10415-10431

44. Meyerhardt, J. A., and Mayer, R. J. (2005) Systemic therapy for colorectal cancer. *N Engl J Med* **352**, 476-487
45. Kopetz, S., Chang, G. J., Overman, M. J., Eng, C., Sargent, D. J., Larson, D. W., Grothey, A., Vauthey, J. N., Nagorney, D. M., and McWilliams, R. R. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *J Clin Oncol* **27**, 3677-3683

46. Bennouna, J., Sastre, J., Arnold, D., Osterlund, P., Greil, R., Van Cutsem, E., von Moos, R., Vieitez, J. M., Bouche, O., Borg, C., Steffens, C. C., Alonso-Orduna, V., Schlichting, C., Reyes-Rivera, I., Bendahmane, B., Andre, T., Kubicka, S., and Investigators, M. L. S. (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol* **14**, 29-37

47. Aya-Bonilla, C., Camilleri, E., Haupt, L. M., Lea, R., Gandhi, M. K., and Griffiths, L. R. (2014) In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL). *BMC Genomics* **15**, 390

48. Ma, J., Lin, J. Y., Alloo, A., Wilson, B. J., Schatton, T., Zhan, Q., Murphy, G. F., Waaga-Gasser, A. M., Gasser, M., Stephen Hodi, F., Frank, N. Y., and Frank, M. H. (2010) Isolation of tumorigenic circulating melanoma cells. *Biochem Biophys Res Commun* **402**, 711-717

49. Gray, E. S., Reid, A. L., Bowyer, S., Calapre, L., Siew, K., Pearce, R., Cowell, L., Frank, M. H., Millward, M., and Ziman, M. (2015) Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. *J Invest Dermatol* **135**, 2040-2048

50. Schmiegel, W., Pox, C., Reinacher-Schick, A., Adler, G., Arnold, D., Fleig, W., Folsch, U. R., Fruhmorgen, P., Graeven, U., Heinemann, V., Hohenberger, W., Holstege, A., Junghering, T., Kopp, I., Kuhlbacher, T., Porschen, R., Propping, P., Riemann, J. F., Rodel, C., Sauer, R., Sauerbruch, T., Schmitt, W., Schmoll, H. J., Seufferlein, T., Seitz, M., Selbmann, H. K., Federal Committee of P., and Health, I. (2010) S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). *Z Gastroenterol* **48**, 65-136

51. Frank, N. Y., Schatton, T., Kim, S., Zhan, Q., Wilson, B. J., Ma, J., Saab, K. R., Osherov, V., Widlund, H. R., Gasser, M., Waaga-Gasser, A. M., Kupper, T. S., Murphy, G. F., and Frank, M. H. (2011) VEGFR-1 expressed by malignant melanoma initiating cells is required for tumor growth. *Cancer Res*

52. Frank, N. Y., Kho, A. T., Schatton, T., Murphy, G. F., Molloy, M. J., Zhan, Q., Ramoni, M. F., Frank, M. H., Kohane, I. S., and Gussoni, E. (2006) Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin. *J Cell Biol* **175**, 99-110

53. Civenni, G., Walter, A., Kobert, N., Mihic-Probst, D., Zipser, M., Belloni, B., Seifert, B., Moch, H., Dummer, R., van den Broek, M., and Sommer, L. (2011) Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. *Cancer Res* **71**, 3098-3109

54. Vuorte, J., Jansson, S. E., and Repo, H. (2001) Evaluation of red blood cell lysing solutions in the study of neutrophil oxidative burst by the DCFH assay. *Cytometry* **43**, 290-296
Table 1. Median OS Times According to Quartiles of ABCB5 expression.

| ΔCt values                  | Median | Lower 95% CI | Upper 95% CI |
|-----------------------------|--------|--------------|--------------|
| 4th quartile: ΔCt <=15.808  | 26.4   | 18.3         | 36.0         |
| 3rd quartile: ΔCt (15.808,16.92725] | 76.7   | 57.9         | ∞            |
| 2nd quartile: ΔCt (16.92725,18.2935] | 88.5   | 88.4         | ∞            |
| 1st quartile: ΔCt >18.2935  | Not reached | -            | -            |
Table 2. OS Cox Model Results According to the Quartiles of ABCB5 expression.

| Predictor   | Comparison | Hazard Ratio | Lower 95% CI | Upper 95% CI | P-value |
|-------------|------------|--------------|--------------|--------------|---------|
| ABCB5       |            |              |              |              | 0.0003  |
| ABCB5 quartile | 3 vs. 4   | 0.50         | 0.23         | 1.06         |         |
| ABCB5 quartile | 2 vs. 4   | 0.25         | 0.11         | 0.58         |         |
| ABCB5 quartile | 1 vs. 4   | 0.13         | 0.05         | 0.35         |         |
| UICC        |            |              |              |              | 0.02    |
| UICC        | 2 vs. 1   | 1.02         | 0.49         | 2.15         |         |
| UICC        | 3 vs. 1   | 0.72         | 0.33         | 1.60         |         |
| UICC        | 4 vs. 1   | 2.60         | 1.02         | 6.61         |         |
FIGURE LEGENDS

Figure 1. ABCB5 as a prognostic marker in CRC. A, Comparison of ABCB5 mRNA expression in PBMCs of CRC patients and healthy controls. Data were analyzed using the unpaired t-test. Error bars indicate s.e.m. ***P < 0.001. B, Evaluation of overall survival (OS) according to quartiles of ABCB5 mRNA expression in PBMCs of CRC patients. The distributions of OS were summarized using the Kaplan-Meier method with 95% confidence intervals (CI) estimated using log (-log (endpoint)) methodology.

Figure 2. Comparative analyses of ABCB5 expression in primary and metastatic CRC cell lines. Representative ABCB5 flow cytometry analyses of the primary tumor-derived SW480 and metastasis-derived SW620 cell lines (A) and the parental COLO741 and metastatic COLO741MET cell lines (B, lower panel). B, upper panel, Schematic illustration of the generation of the metastatic COLO741MET cell line. Bar graphs in A and B depict the comparative quantitative analyses of ABCB5 positivity. Each experiment was performed three times. Data were analyzed using the unpaired t-test. Error bars indicate s.e.m. *P < 0.05, **P < 0.01.

Figure 3. ABCB5 maintains an invasive cell phenotype in human CRC cells. A, Schematic illustration of the in vivo tumor invasion assay. Bar graphs depict the comparison of relative human GAPDH, B2M, PPIA and MRPL19 mRNA levels in PBMCs of mice injected subcutaneously with either COLO741 or COLO741MET cells (n=7 mice per group) (B), or with COLO741MET CONTROL or COLO741MET ABCB5 KD cells (n=6 mice per group) (C, lower panel). C, upper panel, Generation of the COLO741MET ABCB5 KD cell line. The bar graph on the right depicts ABCB5 mRNA expression relative to human GAPDH mRNA levels in COLO741MET CONTROL vs. COLO741MET ABCB5 KD cells; the overall quantitative analyses of ABCB5 positivity by flow cytometry are shown on the right. Data were analyzed using the unpaired t-test. Error bars indicate s.e.m. D, In vitro cell invasion assays for COLO741 vs. COLO741MET and COLO741MET CONTROL vs. COLO741MET ABCB5 KD cell lines, and in vitro cell invasion assays for COLO741MET and SW620 cells treated with either isotype control mAb or ABCB5 mAb. All studies were conducted in triplicates. Representative images of invading Diff-Quik-stained cells (pink) are shown in the respective top panels. Bar graphs in bottom panels illustrate mean numbers of invading cells per well (n=3 independent experiments, each replicate representing sums of invading cells detected in 4 randomly chosen microscopic fields/well). Data were analyzed using the unpaired t-test. Error bars indicate s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 4. Role of ABCB5 in mesenchymal phenotype maintenance. A, Representative images of cultured COLO741 and COLO741MET cells. Brightfield microscopy images are shown in top panels and immunofluorescent β-Actin-stained images (green) on bottom panels. Nuclei were stained with DAPI (blue). The bar graph depicts the quantitative morphometric analysis of cellular elongation, which was computed as Max Feret per Min Feret (the maximum and minimum length, respectively, for all orientations) on the single cell using NIS-Elements Viewer software. Comparative analyses of epithelial (CDH1) and mesenchymal (CDH2 and VIM) marker expression in COLO741 vs. COLO741MET and in SW480 vs. SW620 are shown on the right. B, Effect of mAb- or sh-RNA-mediated ABCB5 blockade on CDH1, CDH2 and VIM expression in COLO741- and SW620 cells as determined by real-time RT PCR and Western blot. Data were analyzed using the unpaired t-test. Error bars indicate s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 5. ABCB5(+) CRC cells express the EMT-sustaining receptor tyrosine kinase AXL, which serves as a mediator of ABCB5-dependent cancer invasion. A, left, A representative flow cytometric analysis of AXL protein expression in an ABCB5 KD vs. a control-transfected cell line. The bar graph illustrates AXL mRNA expression in ABCB5 KD vs. control-transfected human CRC cells. A, right, Western blot analyses of AXL, AKT and phospho-AKT protein expression in either anti-ABCB5 mAb-
treated or isotype control-treated CRC cells. B, Bar graphs depict comparative AXL mRNA and protein expression of sorted ABCB5(+) vs. ABCB5 (-) cells isolated from COLO741, SW620, HT29 or HCT116 CRC cells, as determined by quantitative RT-PCR analyses (left) and flow cytometry (right). For each cell line, triplicate samples were tested. Data analysis was performed using the paired t-test. C, The bar graph illustrates AXL mRNA expression in COLO741 vs. COLO741MET cells. Western blot analyses of AXL, AKT and phospho-AKT protein expression are shown on the right. D, shRNA-mediated ABCB5 KD results in reduced tumor invasion in vivo. The bar graph depicts the comparison of relative human GAPDH, B2M, PPIA and MRPL19 mRNA levels in PBMCs of mice injected subcutaneously with either ABCB5 KD or control-transfected COLO741 cells (n=9 mice per group). E, left, Exogenous overexpression of AXL in ABCB5 KD cells. Representative flow cytometry analysis of AXL protein expression in ABCB5 KD control-transfected (red) vs. ABCB5 KD AXL-transfected (blue) cells. The bar graph depicts AXL mRNA expression in ABCB5 KD control-transfected vs. ABCB5 KD AXL-transfected CRC cells. E, right, AXL restores tumor cell invasion in the setting of ABCB5 blockade. The bar graph depicts the comparison of relative human GAPDH, B2M, PPIA and MRPL19 mRNA levels in PBMCs of mice injected subcutaneously with either AXL-overexpressing ABCB5 KD (n=4 mice per group) or control-transfected ABCB5 KD COLO741 cells (n=6 mice per group). Data were analyzed using unpaired t-tests. Error bars indicate s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 6. ABCB5-mediated EMT induction is dependent on IL-8/AXL signaling cascade. A, left panel. Effect of mAb-mediated ABCB5 blockade on IL-8 secretion by CRC cells. Bar graphs represent comparative quantitative analyses of IL-8 concentrations in culture supernatants obtained from CRC cells treated with either ABCB5 mAb or isotype control mAb (25 µg/mL or 50 µg/mL) as determined by ELISA assays. All studies were conducted in triplicates. The data were analyzed using two-way ANOVA. Error bars indicate s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. A, right panel. Effect of ABCB5 KD on IL-8 secretion by COLO741 cells. The bar graph depicts comparative quantitative analyses of IL-8 in culture supernatants obtained from COLO741 or COLO741-ABCB5 KD cells as determined by ELISA assays. The data were analyzed using unpaired t-test. Error bars indicate s.e.m. **P < 0.01. B, Western blot analyses of AXL expression in either ABCB5 mAb-treated or isotype control-treated CRC cells cultured in the presence of recombinant IL-8. C, Western blot analyses of CDH1, CDH2 and VIM expression in either ABCB5 mAb-treated or isotype control mAb-treated CRC cells cultured in the presence of recombinant IL-8.
Figure 1

A

Peripheral blood ABCB5 mRNA levels (relative to ACTB)

Healthy controls (n=55)  
CRC patients (n=142)

B

Quartiles of ABCB5 mRNA expression levels
(1st quartile-lowest — 4th quartile-highest)

Proportion of CRC patients alive

Months
Figure 5
Figure 6

A

B

C
ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer
Qin Guo, Tanja Grimmig, Gabriel Gonzalez, Anita Giobbie-Hurder, Gretchen Berg, Nolan Carr, Brian J. Wilson, Pallavi Banerjee, Jie Ma, Jason S. Gold, Bisweswar Nandi, Qin Huang, Ana Maria Waaga-Gasser, Christine G. Lian, George F. Murphy, Markus H. Frank, Martin Gasser and Natasha Y. Frank

J. Biol. Chem. published online May 22, 2018

Access the most updated version of this article at doi: 10.1074/jbc.RA118.003187

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts